Design and Synthesis of Active Site Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation in Multiple Myeloma Cells
- 19 March 2012
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (7), 3201-3215
- https://doi.org/10.1021/jm201657x
Abstract
Human farnesyl pyrophosphate synthase (hFPPS) controls intracellular levels of FPP and post-translational prenylation of small GTPase proteins, which are essential for cell signaling and cell proliferation. Clinical investigations provide evidence that N-BP inhibitors of hFPPS are disease modifying agents that improve survival of multiple myeloma (MM) patients via mechanisms unrelated to their skeletal effects. A new series of N-BPs was designed that interact with a larger portion of the GPP subpocket, as compared to the current therapeutic drugs, and rigidify the (364)KRRK(367) tail of hFPPS in the closed conformation in the absence of IPP. An analogue of this series was used to demonstrate inhibition of the intended biological target, resulting in apoptosis and down-regulation of ERK phosphorylation in human MM cell lines.Keywords
This publication has 38 references indexed in Scilit:
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Molecular Targets of the Nitrogen Containing Bisphosphonates: The Molecular Pharmacology of Prenyl Synthase InhibitionCurrent Pharmaceutical Design, 2010
- The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitroBone, 2009
- Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigensImmunological Reviews, 2007
- Activity of Nitrogen-Containing and Non-Nitrogen-Containing Bisphosphonates on Tumor Cell LinesJournal of Medicinal Chemistry, 2006
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences, 2006
- Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate DrugsChemMedChem, 2006
- A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen‐containing bisphosphonatesBritish Journal of Pharmacology, 2006
- A Peptide Prodrug Approach for Improving Bisphosphonate Oral AbsorptionJournal of Medicinal Chemistry, 2000